Contribute Try STAT+ Today

Allergan (AGN) is appealing to the Supreme Court in an effort to stall generic competition to its best-selling dry-eye drug Restasis. But the pharma giant also faces a threat on a different front: a small Canadian drug maker advancing its own medicine that could prove superior to Restasis.

The experimental dry-eye medicine is called VOS, a shorthand moniker for voclosporin ophthalmic solution. It’s being developed by Aurinia Pharmaceuticals (AUPH), a drug maker based in Victoria, the capital of British Columbia located on the southern tip of Vancouver Island.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Your daily dose of news in health and medicine

Privacy Policy